Breaking barriers to novel analgesic drug development
AS Yekkirala, DP Roberson, BP Bean… - Nature reviews Drug …, 2017 - nature.com
Acute and chronic pain complaints, although common, are generally poorly served by
existing therapies. This unmet clinical need reflects a failure to develop novel classes of …
existing therapies. This unmet clinical need reflects a failure to develop novel classes of …
[引用][C] Breaking barriers to novel analgesic drug development
AS Yekkirala, DP Roberson, BP Bean… - Nature Reviews Drug …, 2017 - cir.nii.ac.jp
Breaking barriers to novel analgesic drug development | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
Breaking barriers to novel analgesic drug development
AS Yekkirala, DP Roberson… - Nature reviews. Drug …, 2017 - pubmed.ncbi.nlm.nih.gov
Acute and chronic pain complaints, although common, are generally poorly served by
existing therapies. This unmet clinical need reflects a failure to develop novel classes of …
existing therapies. This unmet clinical need reflects a failure to develop novel classes of …
[PDF][PDF] Breaking barriers to novel analgesic drug development
AS Yekkirala, DP Roberson, BP Bean… - NATURE REVIEWS …, 2017 - researchgate.net
Acute and chronic pain complaints, although common, are generally poorly served by
existing therapies. This unmet clinical need reflects a failure to develop novel classes of …
existing therapies. This unmet clinical need reflects a failure to develop novel classes of …
[HTML][HTML] Breaking barriers to novel analgesic drug development
AS Yekkirala, DP Roberson, BP Bean… - Nature reviews. Drug …, 2017 - ncbi.nlm.nih.gov
Acute and chronic pain complaints, while very common, are generally poorly served by
existing therapies. The unmet clinical need reflects the failure in developing novel classes of …
existing therapies. The unmet clinical need reflects the failure in developing novel classes of …
Breaking barriers to novel analgesic drug development
AS Yekkirala, DP Roberson, BP Bean… - Nature Reviews Drug …, 2017 - nature.com
Acute and chronic pain complaints, although common, are generally poorly served by
existing therapies. This unmet clinical need reflects a failure to develop novel classes of …
existing therapies. This unmet clinical need reflects a failure to develop novel classes of …
Breaking barriers to novel analgesic drug development.
AS Yekkirala, DP Roberson, BP Bean… - Nature reviews. Drug …, 2017 - europepmc.org
Acute and chronic pain complaints, while very common, are generally poorly served by
existing therapies. The unmet clinical need reflects the failure in developing novel classes of …
existing therapies. The unmet clinical need reflects the failure in developing novel classes of …
Breaking barriers to novel analgesic drug development
AS Yekkirala, DP Roberson, BP Bean… - Nature Reviews Drug …, 2017 - go.gale.com
Acute and chronic pain complaints, although common, are generally poorly served by
existing therapies. This unmet clinical need reflects a failure to develop novel classes of …
existing therapies. This unmet clinical need reflects a failure to develop novel classes of …
Breaking barriers to novel analgesic drug development
AS Yekkirala, DP Roberson, BP Bean… - Nature reviews. Drug …, 2017 - ncbi.nlm.nih.gov
The compounds APD371, LY2828360, S-777469 and KHK6188 were incorrectly referred to
as inhibitors of the cannabinoid receptors CB1 and CB2 in Table 1, when they are …
as inhibitors of the cannabinoid receptors CB1 and CB2 in Table 1, when they are …
Breaking barriers to novel analgesic drug development.
AS Yekkirala, DP Roberson, BP Bean… - Nature reviews. Drug …, 2017 - europepmc.org
Acute and chronic pain complaints, while very common, are generally poorly served by
existing therapies. The unmet clinical need reflects the failure in developing novel classes of …
existing therapies. The unmet clinical need reflects the failure in developing novel classes of …